Navigation Links
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Date:10/27/2010

PRINCETON, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, October 31, 2010 starting at 7:00pm ET. During this webcast, management will review Pharmasset's progress on the programs that are the subject of presentations at AASLD.To access a simultaneous webcast of this event via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

The following abstracts are available on the AASLD website (AASLD.org).

RG7128Abstract 81"High rates of early viral response, promising safety profile and lack of resistance related breakthrough in HCV GT 1/4 patients treated with RG7128 plus PegIFN alfa-2a (40KD)/RBV: Planned Week 12 interim analysis from the PROPEL study" will be presented in the HCV Clinical Trials session on Sunday October 31st at 5:15pm ET. Authors of the study are Jensen, D. M. et al.

Abstract 799"No evidence of drug resistance or baseline S282T resistance mutation among GT1 and GT4 HCV infected patients on nucleoside polymerase inhibitor RG7128 and Peg-IFN/RBV combination treatment for up to 12 weeks: Interim analysis from the PROPEL study" will be presented in a poster session on Sunday October 31st. Authors of the study are Le Pogam, S. et al.

PSI-7977Abstract 806"High Rapid Virologic Response (RVR) with PSI-7977 Daily Dosing plus PEG-IFN/RBV in a 28-day Phase 2a Trial" will be presented in a poster sessi
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset to Present at the JMP Healthcare Conference
2. Pharmasset to Present at the UBS Global Life Sciences Conference
3. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
4. Pharmasset to Present at the 28th Annual JPMorgan Healthcare Conference
5. Pharmasset Reports Fiscal Year End 2009 Financial Results
6. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
7. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
8. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
9. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
10. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
11. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 5, 2015 /CNW Telbec/ - Ergoresearch Ltd ... and known under the « Équilibre, orthèses ... the transaction previously announced on April 23, 2015 regarding ...  shares of Orthoconcept (2008) inc.   The ... shares (TSXV: ERG) to the vending shareholder, namely 9211-5096 ...
(Date:5/5/2015)... Valley Medical Center, named a Top 100 Hospitals® in the ... to deploy the wireless Leaf Patient Monitoring System in its ... labor and risk of caesarian births. Studies show ... is reduced in mothers who are upright and mobile during ... epidurals and tend to lie in their labor room beds. ...
(Date:5/5/2015)... , May 5, 2015  IQPC,s 19 th ... announce the chairman of the Summit Mr. Phani Bidarahalli ... will be joined by the expert speaker faculty including senior ... May 11 – 12, at The Hotel Kabuki in ... is available for download on the event website, which can ...
Breaking Medicine Technology:Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 2Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 3Desert Valley Medical Center First to Use Leaf Patient-Wearable Technology to Help Reduce C-Sections, Speed Labor 4Phani Bidarahalli from Wipro to chair the upcoming 19th Software Design for Medical Devices Summit in San Francisco 2
... VEGAS, June 28, 2011 The pharmacy made the decision ... of its customers. The fact Xpressdelivery.com offered cheapest Viagra ... of the world, and their desire to see more drugs ... was only logical. After giving the matter most careful consideration ...
... June 28, 2011 In strong collaboration with clinical ... compact version of the LokomatPro that offers greater system ... device in 2001, the LokomatPro has established itself as ... patients with neurological diseases and injuries resulting in gait ...
Cached Medicine Technology:Xpressdelivery.com Expanded Its Drug List Adding Most Demanded Generic Medications 2Hocoma Launches New Version of its Established Gait Training Device LokomatPro 2
(Date:5/5/2015)... DC (PRWEB) May 05, 2015 ... Optimity) will present at the 24th ... at 1:15 p.m. MT in Scottsdale, AZ. WEDI, ... nation’s leading nonprofit authority on the use of ... exchange. Donald Graf, National Director of Telemedicine for ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 From ... the established leader in enabling enterprise collaboration ... to help customers speed up and simplify the ... technologies, AvePoint Solutions for Office 365 ... faster while ensuring sustainable user adoption and effectively ...
(Date:5/5/2015)... Sunny skies and cool temperatures made for great ... runners and walkers participated in Global Lyme Alliance’s (GLA) inaugural ... , The 5K and 10K runs and 1-and 3-mile walks ... raise funds for tick-borne disease research. The “Lyme Walk and ... merger of Lyme Research Alliance (LRA) and Tick-Borne Disease ...
(Date:5/5/2015)... " QuickPick Travel ” was featured on ... a look small, medium, and large businesses making an impact ... a business expert, conducted the business review and shared with ... to three weeks of vacation for free. , Vacations are ... explore the world. And when people are preparing for vacations, ...
(Date:5/5/2015)... 2015 Information Innovators Inc. ... the federal government, today announced its acquisition of ... provides solutions exclusively to federal government customers through ... cyber security, health services, and program management support. ... credentials as a Third Party Assessment Organization (3PAO) ...
Breaking Medicine News(10 mins):Health News:Optimity Advisors’ Hiliary Critchley, Telemedicine Expert, to Speak at WEDI Conference May 20th in Scottsdale, AZ 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 2Health News:AvePoint Unveils New Solutions for Microsoft Office 365 & Azure at Microsoft Ignite 2015 3Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 2Health News:1st Annual “Lyme Walk & Run” Event a Huge Success 3Health News:A Platform to Plan the Perfect Vacation was Featured on NewsWatch Television 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
... REVENUES UP 35% VERSUS FULL YEAR 2006, BRANCHBURG, ... today reported financial results for the fourth,quarter and full ... Executive Officer, will host a conference call today at ... year financial results., Fourth Quarter 2007 Results, ...
... Physicians Report Satisfaction with GlaxoSmithKline,s Advair and,Boehringer ... Novel, Anti-Inflammatory Drug, According to a New ... Feb. 27 Decision Resources, one of ... on pharmaceutical and,healthcare issues, finds that surveyed ...
... EXTON, Pa., Feb. 27 ViroPharma Incorporated,(Nasdaq: VPHM ) ... months ended December 31, 2007., Key events since ... Drug Designation received for Camvia(TM) (maribavir); -- Patient enrollment ... cell and solid organ transplant patients; ...
... Body, Mind & Spirit, VAIL, Colo., Feb. ... healthcare, Next Step(R) Institute of Integrative,Medicine, Inc., headquartered ... recently announced its 2008 series of life-changing,Wellness Weeks ... Institute Wellness Weeks are six-night, five-day programs,that promote ...
... Overweight Hispanic children with normal blood glucose (sugar) levels showed ... to developing both type 2 diabetes and cardiovascular disease, says ... Center. , The study, published in the March issue of ... already known to be at high risk for developing type ...
... new article suggests that the United States government ... Cuba into a biomedical research institute dedicated to ... the open-access journal PLoS Neglected Tropical Diseases, Editor-in-Chief ... be in an optimal position to directly address ...
Cached Medicine News:Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:LifeCell Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status 2Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 9Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 10Health News:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results 11Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 2Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 3Health News:Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks 4Health News:Overweight Hispanic children shown to have vascular inflammation 2Health News:From detainee facility to health advocacy center: A new role for Guantanamo? 2
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
Amylase (EPS-G7, kinetics), Wavelength: 405 nm. Linear range; 5-1500 IU/L....
Intended for the quantitative determination of alphaamylase activity in serum. Single vial, dry powder reagent. Reaction: Kinetic. Wavelength: 405 nm. Linearity: 2000 U/L at 37C....
For the direct, colorimetric determination of calcium in human serum or urine. Linearity: 20 mg/dl....
Medicine Products: